Differential MSH2 promoter methylation in blood cells of Neurofibromatosis type 1 (NF1) patients

被引:21
|
作者
Titze, Sabrina [1 ]
Peters, Hartmut [2 ]
Waehrisch, Sandra [1 ]
Harder, Thomas [3 ]
Guse, Katrin [1 ]
Buske, Annegret [2 ]
Tinschert, Sigrid [2 ,4 ]
Harder, Anja [1 ]
机构
[1] Charite, Inst Neuropathol, D-10117 Berlin, Germany
[2] Charite, Inst Med Genet, D-10117 Berlin, Germany
[3] Charite, Clin Obstet, Res Grp Expt Obstet, D-10117 Berlin, Germany
[4] Tech Univ Dresden, Inst Clin Genet, Med Fac Carl Gustav Carus, Dresden, Germany
关键词
neurofibromatosis type 1; NF1; mismatch repair; MSH2; neurofibroma; methylation; modifier; SCHWANN-CELLS; HIGH-FREQUENCY; HMLH1; GENE; MUTATION; HYPERMETHYLATION; EXPRESSION; CANCER; HMSH2; IDENTIFICATION; DEFECTS;
D O I
10.1038/ejhg.2009.129
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurofibromatosis type 1 (NF1) is caused by NF1 gene mutations. The phenotype is highly variable, with 'modifiers' being discussed as potential determinants. Mismatch repair deficiency was shown to cause NF1 mutations, but constitutional mutation of mismatch repair genes was identified only once in a NF1 patient. We aimed to analyze whether DNA methylation of mismatch repair gene promoters, known to lead to transcriptional silencing, is associated with increased tumor load in NF1 defined by the number of cutaneous neurofibromas. Leukocyte DNA of 79 controls and 79 NF1 patients was investigated for methylation of mismatch repair genes MLH1, MSH2, MSH6, and PMS2 by methylation-specific PCR and pyrosequencing. MLH1, MSH6, and PMS2 promoters were not methylated. By contrast, we found promoter methylation of MSH2 with a higher rate of methylation in NF1 patients compared with controls. Furthermore, when comparing NF1 patients with a low vs those with a high number of cutaneous neurofibromas, MSH2 promoter methylation was significantly different. In patients with a high tumor burden, methylation of two (out of six) CpGs was enhanced. This finding was not confounded by age. In conclusion, enhanced methylation involving transcription start points of mismatch repair genes, such as MSH2 in NF1, has not been described so far. Methylation-induced variability of MSH2 gene expression may lead to variable mismatch repair capacity. Our results may point toward a role of MSH2 as a modifier for NF1, although the amount of DNA methylation and subsequent gene expression in other cell types of NF1 patients needs to be elucidated. European Journal of Human Genetics (2010) 18, 81-87; doi:10.1038/ejhg.2009.129; published online 29 July 2009
引用
收藏
页码:81 / 87
页数:7
相关论文
共 50 条
  • [31] Human stem cell modeling in neurofibromatosis type 1 (NF1)
    Wegscheid, Michelle L.
    Anastasaki, Corina
    Gutmann, David H.
    EXPERIMENTAL NEUROLOGY, 2018, 299 : 270 - 280
  • [32] Novel mutations involving the NF1 gene coding sequence in neurofibromatosis type 1 patients from Taiwan
    Ming-Tzen Liu
    Jih-Shyun Su
    Chun-Yu Huang
    Shih-Feng Tsai
    Journal of Human Genetics, 2003, 48 : 545 - 549
  • [33] Novel mutations involving the NF1 gene coding sequence in neurofibromatosis type 1 patients from Taiwan
    Liu, MT
    Su, JS
    Huang, CY
    Tsai, SF
    JOURNAL OF HUMAN GENETICS, 2003, 48 (10) : 545 - 549
  • [34] Accurate Classification of NF1 Gene Variants in 84 Italian Patients with Neurofibromatosis Type 1
    Stella, Alessandro
    Lastella, Patrizia
    Loconte, Daria Carmela
    Bukvic, Nenad
    Varvara, Dora
    Patruno, Margherita
    Bagnulo, Rosanna
    Lovaglio, Rosaura
    Bartolomeo, Nicola
    Serio, Gabriella
    Resta, Nicoletta
    GENES, 2018, 9 (04)
  • [35] Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1
    Nystrom, A. M.
    Ekvall, S.
    Allanson, J.
    Edeby, C.
    Elinder, M.
    Holmstrom, G.
    Bondeson, M. L.
    Anneren, G.
    CLINICAL GENETICS, 2009, 76 (06) : 524 - 534
  • [36] Identification of the NF1 gene mutation in Korean families with neurofibromatosis type 1
    Jo, Yong Hwa
    Kim, Hye Ok
    Song, Hae-Ryong
    Yoon, Kyung-Sik
    GENES & GENOMICS, 2014, 36 (01) : 11 - 15
  • [37] BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation
    Iwamoto, Takashi
    Yamamoto, Noriaki
    Taguchi, Tetsuya
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (01) : 69 - 77
  • [38] NF1 single and multi-exons copy number variations in neurofibromatosis type 1
    Imbard, Apolline
    Pasmant, Eric
    Sabbagh, Audrey
    Luscan, Armelle
    Soares, Magali
    Goussard, Philippe
    Blanche, Helene
    Laurendeau, Ingrid
    Ferkal, Salah
    Vidaud, Michel
    Pinson, Stephane
    Bellanne-Chantelot, Christine
    Vidaud, Dominique
    Wolkenstein, Pierre
    Parfait, Beatrice
    JOURNAL OF HUMAN GENETICS, 2015, 60 (04) : 221 - 224
  • [39] Prevalence, Type, and Molecular Spectrum of NF1 Mutations in Patients with Neurofibromatosis Type 1 and Congenital Heart Disease
    Pinna, Valentina
    Daniele, Paola
    Calcagni, Giulio
    Mariniello, Lucio
    Criscione, Roberta
    Giardina, Chiara
    Lepri, Francesca Romana
    Hozhabri, Hossein
    Alberico, Angela
    Cavone, Stefania
    Morella, Annunziata Tina
    Mandile, Roberta
    Annunziata, Francesca
    Di Giosaffatte, Niccolo
    D'Asdia, Maria Cecilia
    Versacci, Paolo
    Capolino, Rossella
    Strisciuglio, Pietro
    Giustini, Sandra
    Melis, Daniela
    Digilio, Maria Cristina
    Tartaglia, Marco
    Marino, Bruno
    De Luca, Alessandro
    GENES, 2019, 10 (09)
  • [40] Neurofibromatosis type 1 (NF1) with an unusually severe phenotype due to digeny for NF1 and ryanodine receptor 1 associated myopathy
    Martin, Florence
    Kana, Veronika
    Mori, Andrea Capone
    Fischer, Dirk
    Parkin, Nicolas
    Boltshauser, Eugen
    Rushing, Elisabeth Jane
    Klein, Andrea
    EUROPEAN JOURNAL OF PEDIATRICS, 2014, 173 (12) : 1691 - 1694